Last reviewed · How we verify

KM-001 1% cream 12 weeks treatment

Kamari Pharma Ltd · Phase 1 active Small molecule

KM-001 1% cream 12 weeks treatment is a Small molecule drug developed by Kamari Pharma Ltd. It is currently in Phase 1 development. Also known as: Cohort 1.

At a glance

Generic nameKM-001 1% cream 12 weeks treatment
Also known asCohort 1
SponsorKamari Pharma Ltd
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about KM-001 1% cream 12 weeks treatment

What is KM-001 1% cream 12 weeks treatment?

KM-001 1% cream 12 weeks treatment is a Small molecule drug developed by Kamari Pharma Ltd.

Who makes KM-001 1% cream 12 weeks treatment?

KM-001 1% cream 12 weeks treatment is developed by Kamari Pharma Ltd (see full Kamari Pharma Ltd pipeline at /company/kamari-pharma-ltd).

Is KM-001 1% cream 12 weeks treatment also known as anything else?

KM-001 1% cream 12 weeks treatment is also known as Cohort 1.

What development phase is KM-001 1% cream 12 weeks treatment in?

KM-001 1% cream 12 weeks treatment is in Phase 1.

Related